Ehave Inc Stock Price, News & Analysis

Ehave, Inc. (OTC Pink: EHVVF) announced the filing of a Form 6-K with the SEC, revealing a Letter of Intent (LOI) to acquire Moksha Digital Software. This strategic move is projected to significantly enhance revenues, escalating from $10.19 million in the first year to approximately $150.42 million by year five. The Form 6-K also outlines fund utilization and a business plan over five years. The full filing can be accessed at the SEC's website.

Ehave, Inc. (EHVVF) announced a Letter of Intent to acquire Moksha Digital Software Pvt. Ltd., a healthcare software provider known for its FDA-cleared CuriePACS and CurieRIS solutions. The acquisition aims to enhance Ehave’s digital therapeutics portfolio and leverage Moksha's established sales channels to facilitate growth. Moksha Digital has a proven track record with expertise derived from founders with extensive backgrounds in leading companies. This strategic move is expected to expand Ehave's reach in medical imaging, particularly in the psychedelic and clinical trial sectors.

Ehave, Inc. (OTC Pink: EHVVF) has disclosed through a Form 6-K filing with the SEC that it entered into a Research Project Agreement with The University of Melbourne on July 2, 2021. This agreement aims to gather data and biomarkers for targeting Hallucinogen Persisting Perception Disorder (HPPD). Ehave focuses on digital therapeutics for brain disorders and offers platforms like the Ehave Telemetry Portal and Ehave Infinity Portal, designed to enhance patient care through data-driven insights.

Ehave, Inc. (EHVVF) announced the licensing of advanced AI technology from Vastmindz to enhance its Ehave Dashboard and Ehave Medical App. This proprietary computer vision technology enables the apps to assess physiological conditions like heart rate and oxygen saturation by analyzing facial skin light absorption. The integration aims to improve remote healthcare by providing seamless data aggregation and enhancing interactions between healthcare providers and patients. CEO Ben Kaplan highlighted the technology's role in democratizing healthcare and improving treatment outcomes.

Ehave, Inc. (EHVVF) announces a partnership with a globally recognized university to investigate Hallucinogen Persisting Perception Disorder (HPPD). The study, lasting 12 months, aims to gather data and bio-markers to create screening products and a revenue model. It consists of three stages: identifying visual task assessments, expanding the study to a larger sample, and developing a web-based test platform. CEO Ben Kaplan emphasized the importance of this initiative for understanding HPPD and enhancing treatment safety.

Ehave, Inc. (EHVVF) announced plans for large-scale studies on hallucinogen-persisting perception disorder (HPPD), which affects a minority of psychedelic users with lingering visual disturbances. CEO Ben Kaplan emphasized the intention to explore genetic predispositions and develop visual processing tests within their therapeutic app. The company aims to be an industry leader in minimizing treatment side effects. This research could represent the largest patient study of HPPD to date, with potential implications for broader psychedelic therapy acceptance.

Ehave, Inc. (EHVVF) announced a partnership with Health Wizz and BurstIQ to enhance data integrity and patient privacy. This collaboration aims to allow patients to securely share medical data with providers and researchers, crucial for understanding treatments for mental health and substance use disorders. The Ehave Dashboard, developed with a major children's hospital in Canada, will utilize AI and blockchain technology to streamline health processes, enabling better patient outcomes. CEO Ben Kaplan emphasized the importance of data integrity in improving mental health care.

Ehave, Inc. (EHVVF) announced the hiring of an Institutional Review Board (IRB) to oversee its upcoming ketamine clinical trials in Miami with Tristar Wellness. This crucial step ensures the safety of participants and compliance with research protocols. The company plans to launch its KetaDASH platform for at-home ketamine therapy, aiming to enhance patient access and clinic revenues. Ehave is negotiating to franchise the KetaDASH platform across the U.S., and management highlights the potential to expand ketamine therapy research beyond mental health.

Ehave, Inc. (OTC Pink: EHVVF) announced that Dr. Bankole A. Johnson has joined its Medical Advisory Board. Dr. Johnson, a renowned psychiatrist known for his research in psychopharmacology and addiction, will advise on human trials related to cognitive and psychedelic therapies and mental health platforms. His previous roles include chairman at the University of Virginia’s Psychiatry Department and founder of Adial Pharmaceuticals. Dr. Johnson aims to integrate biological mechanisms of addiction with psychedelic medicine to improve patient care.